Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
– Poster presentations highlight clinical data across Cybin’s CYB003 deuterated psilocin and DMT programs – TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
– 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses of CYB003 – – Robust, long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale (“ MADRS ”) score compared to baseline at 12 months
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
– 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses of CYB003 – – Robust, long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale (“ MADRS ”) score compared to baseline at 12 months
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
– PARADIGM ™ program comprises two 12-week randomized, placebo-controlled studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND) – – APPROACH ™ : A P hase III, P lacebo-Controlled, R andomized, Double-Blind Trial of O ral Doses of CYB003 to A ssess C ombined Safety
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
– CEO Doug Drysdale to speak on panel about novel approaches to mental health treatments on November 13, 2024 – TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry platform company committed to
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
– The Company is evaluating non-hallucinogenic dosing of CYB005 preclinical candidate molecules for the treatment of CNS disorders – – Cybin’s sector-leading intellectual property portfolio now includes over 70 granted patents and more than 220 patent applications pending – TORONTO–(BUSINESS
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
– Company is on track to initiate its global Phase 3 pivotal program for CYB003 in Major Depressive Disorder (“MDD”) imminently – – Cybin welcomes Dr. Mirza Rahman as Senior Vice President, Patient Safety & Pharmacovigilance and Dr. Marcelo Gutierrez as Vice President, Clinical Pharmacology – –